{
    "id": "5c56033607647bbc4b00000c",
    "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the available information about Tisagenlecleucel and its effectiveness in treating B-Cell Lymphoma. Tisagenlecleucel is a CAR-T cell therapy, which is a type of immunotherapy that involves genetically modifying a patient's T cells to recognize and attack cancer cells. CAR-T cell therapy has shown promise in treating various types of blood cancers, including B-Cell Lymphoma. However, the effectiveness of Tisagenlecleucel specifically for B-Cell Lymphoma needs to be evaluated based on available clinical data and research studies. A quick review of the provided documents does not explicitly mention Tisagenlecleucel, but we can make an educated inference based on the context of CAR-T cell therapy and its applications in treating B-cell malignancies. CAR-T cell therapy has shown significant activity in treating certain types of B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. While the provided documents do not specifically mention Tisagenlecleucel, the general context suggests that CAR-T cell therapy, including Tisagenlecleucel, may be effective in treating B-Cell Lymphoma. However, the effectiveness and safety of Tisagenlecleucel for B-Cell Lymphoma would require specific clinical trial data and research studies to confirm its efficacy and optimal dosing regimen. Given the information provided, the best answer would be based on the general effectiveness of CAR-T cell therapy in treating B-cell malignancies.\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_8690",
            "title": "InternalMed_Harrison",
            "content": "At least two newer anti-CD20 monoclonal antibodies have 703 become available, ofatumumab and obinutuzumab. Both have activity in previously treated patients. Agents targeting signaling pathways, such as ibrutinib, an irreversible inhibitor of Bruton\u2019s tyrosine kinase, and idelalisib, an inhibitor of phosphoinositide3-kinase delta, also have antitumor effects. The ideal combination and sequence of these therapies have not been defined. Extranodal Marginal Zone B-Cell Lymphoma of MALT Type Extranodal marginal zone B-cell lymphoma of MALT type (MALT lymphoma) makes up ~8% of non-Hodgkin\u2019s lymphomas. This small cell lymphoma presents in extranodal sites. It was previously considered a small lymphocytic lymphoma or sometimes a pseudolymphoma. The recognition that the gastric presentation of this lymphoma was associated with H. pylori infection was an important step in recognizing it as a separate entity. The clinical characteristics of MALT lymphoma are presented in Table 134-10."
        },
        {
            "id": "Surgery_Schwartz_2437",
            "title": "Surgery_Schwartz",
            "content": "lower incidence of car-diovascular risk factors including metabolic lipid disorders, hypertension, neurotoxicity, glucose abnormalities, and adverse cosmetic effects. Except for the increased risk of malignancy, the more favorable adverse effect profile of belatacept and its convenient monthly dosing schedule may make it an attrac-tive option for maintenance of immunosuppression, possibly improving compliance.31,32HUMORAL REJECTIONRituximabA chimeric anti-CD20 (anti-B cell) monoclonal antibody, ritux-imab is currently FDA approved for treating several types of lymphoma. The CD20 antigen is expressed early in the B-cell cycle but is absent on mature plasma cells. The variable region binds to CD20 through three different mechanisms: (a) antibody-dependent cell cytotoxicity, (b) complement-dependent cell killing, and (c) induction of apoptotic cell death. The use of Brunicardi_Ch11_p0355-p0396.indd 36201/03/19 6:53 PM 363TRANSPLANTATIONCHAPTER 11rituximab has grown to include the"
        },
        {
            "id": "InternalMed_Harrison_6403",
            "title": "InternalMed_Harrison",
            "content": "tumor-regulAtory ANtiboDies Humanized antibodies against the CD20 molecule expressed on B cell lymphomas (rituximab and ofatumumab) are exemplary of antibodies that affect both signaling events driving lymphomagenesis as well as activating immune responses against B cell neoplasms. They are used as single agents and in combination with chemotherapy and radiation in the treatment of B cell neoplasms. Obinutuzumab is an antibody with an altered glycosylation that enhances its ability to fix complement; it is also directed against CD20 and is of value in chronic lymphocytic leukemia. It seems to be more effective in this setting than rituximab."
        },
        {
            "id": "Pharmacology_Katzung_6173",
            "title": "Pharmacology_Katzung",
            "content": "cellular cytotoxicity, and induction of apoptosis in malignant lymphoma cells and in B cells involved in the pathogenesis of rheumatoid arthritis and granulomatosis and polyangiitis. In lymphoma this drug appears to be synergistic with chemotherapy (eg, fludarabine, CHOP; see Chapter 54). Anemia or neutropenia is an important adverse effect, which can be countered with granulocyte colony-stimulating factor (G-CSF). Other adverse effects include hypotension, rash, gastrointestinal disturbance, fever, and fatigue."
        },
        {
            "id": "InternalMed_Harrison_8739",
            "title": "InternalMed_Harrison",
            "content": "Treatment regimens appropriate for other aggressive lymphomas, such as diffuse large B-cell lymphoma, should be used in patients with anaplastic large T/null-cell lymphoma, with the exception that the B-cell\u2013specific antibody, rituximab, is omitted. Surprisingly, given the anaplastic appearance, this disorder has the best survival rate of any aggressive lymphoma. The 5-year survival is >75%. While traditional prognostic factors such as the IPI predict treatment outcome, overexpression of the ALK protein is an important prognostic factor, with patients overexpressing this protein having a superior treatment outcome. The ALK inhibitor crizotinib appears highly active as well. In addition, the CD30 immunotoxin, brentuximab vedotin, is active in the disease."
        },
        {
            "id": "Pharmacology_Katzung_6001",
            "title": "Pharmacology_Katzung",
            "content": "The treatment of Hodgkin\u2019s lymphoma has undergone dramatic evolution over the last 40 years. This lymphoma is now widely recognized as a B-cell neoplasm in which the malignant Reed-Sternberg cells have rearranged VH genes. In addition, the Epstein-Barr virus genome has been identified in up to 80% of tumor specimens."
        },
        {
            "id": "InternalMed_Harrison_8679",
            "title": "InternalMed_Harrison",
            "content": "The differential diagnosis of typical B-cell CLL is extensive (Table 134-1). Immunophenotyping will eliminate the T-cell disorders and can often help sort out other B-cell malignancies. For example, only mantle cell lymphoma and typical B-cell CLL are usually CD5 positive. Typical B-cell small lymphocytic lymphoma can be confused with other B-cell disorders, including lymphoplasmacytic lymphoma (i.e., the tissue manifestation of Waldenstr\u00f6m\u2019s macroglobulinemia), nodal marginal zone B-cell lymphoma, and mantle cell lymphoma. In addition, some small lymphocytic lymphomas have areas of large cells that can lead to confusion with diffuse large B-cell lymphoma. An expert hematopathologist is vital for making this distinction."
        },
        {
            "id": "Surgery_Schwartz_2486",
            "title": "Surgery_Schwartz",
            "content": "for certain types of tumors, espe-cially at advanced stages or those with a high risk of recurrence (e.g., melanoma, lymphoma, renal cell cancer, breast cancer, colon cancer), a delay of at least 5 years is advisable. Accord-ing to the Israel Penn International Transplant Tumor Registry, tumor recurrence posttransplant is not infrequent: the recurrence rate is 67% in patients with multiple myeloma, 53% in nonme-lanocytic skin cancer, 29% in bladder cancer, and 23% in breast cancer.75Infections. A thorough history of infections and immuniza-tions should be obtained from transplant candidates, who need all recommended age-appropriate vaccinations according to the Centers for Disease Control and Prevention (CDC) guidelines. Ideally, vaccinations should be completed at least 4 to 6 weeks before the kidney transplant takes place. Immunosuppressive medications blunt the immune response and reduce the effec-tiveness of vaccinations; even more important, with attenuated vaccines,"
        },
        {
            "id": "InternalMed_Harrison_8716",
            "title": "InternalMed_Harrison",
            "content": "Malignancies of Lymphoid Cells 706 be expected to achieve a complete remission, and 50\u201370% of complete responders will be cured. The chances for a favorable response to treatment are predicted by the IPI. In fact, the IPI was developed based on the outcome of patients with diffuse large B-cell lymphoma treated with CHOP-like regimens. For the 35% of patients with a low IPI score of 0\u20131, the 5-year survival is >70%, whereas for the 20% of patients with a high IPI score of 4\u20135, the 5-year survival is ~20%. The addition of rituximab to CHOP has improved each of those numbers by ~15%. A number of other factors, including molecular features of the tumor, levels of circulating cytokines and soluble receptors, and other surrogate markers, have been shown to influence prognosis. However, they have not been validated as rigorously as the IPI and have not been uniformly applied clinically. Because a number of patients with diffuse large B-cell lymphoma are either initially refractory to therapy"
        },
        {
            "id": "InternalMed_Harrison_8767",
            "title": "InternalMed_Harrison",
            "content": "Clinical presentation is generally from symptoms of splenomegaly or incidental detection of an elevated white blood cell (WBC) count. The clinical course can be rapid. The cells express surface IgM (with or without IgD) and typical B-cell markers (CD19, CD20, CD22). CD23 is absent, and about one-third of cases express CD5. The CD5 expression along with the presence of the t(11;14) translocation in 20% of cases leads to confusion in distinguishing B-PLL from the leukemic form of mantle cell lymphoma. No reliable criteria for the distinction have emerged. About half of patients have mutation or loss of p53, and deletions have been noted in 11q23 and 13q14. Nucleoside analogues like fludarabine and cladribine and combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]) have produced responses. CHOP plus rituximab may be more effective than CHOP alone, but the disease is sufficiently rare that large series have not been reported. Splenectomy can produce"
        },
        {
            "id": "Neurology_Adams_5085",
            "title": "Neurology_Adams",
            "content": "One trial has demonstrated a 3 month benefit for progression-free survival, but not for overall survival, with the early use of bevicizumab with temozolamide and radiation (Gilbert et al); its use is largely restricted to clinical trials. This anti-VEGF therapy improves the imaging appearance (less edema, small area of enhancement) but fails to inhibit tumor spread. In the field of experimental therapeutics, adoptive T cells (chimeric antigen receptor \u2013T-cell therapy, CAR-T), which had success with leukemia and lymphoma, has demonstrated efficacy in very few studied cases of metastatic glioblastoma (Brown et al)."
        },
        {
            "id": "Pediatrics_Nelson_3358",
            "title": "Pediatrics_Nelson",
            "content": "T-cell lymphoblastic lymphoma and anaplastic large cell lymphoma generally are treated with aggressive multidrug regimens similar to the regimens used in ALL. The main drugs used in the treatment of mature B-cell NHL are cyclophosphamide, moderateto high-dose methotrexate, cytarabine, doxorubicin, ifosfamide, and etoposide. Surgery and radiation therapy rarely are used because the disease is rarely localized and is highly sensitive to chemotherapy. The short-term complications from the treatment of lymphoma are similar to other pediatric malignancies and commonly include immunosuppression, related sequelae from myelosuppression, nausea, vomiting, and alopecia. Late adverse effects include second malignant neoplasms (acute myeloid leukemia or myelodysplasia, thyroid malignancies, and breast cancer), hypothyroidism, impaired soft tissue and bone growth, cardiac dysfunction, and pulmonary fibrosis."
        },
        {
            "id": "Immunology_Janeway_3269",
            "title": "Immunology_Janeway",
            "content": "Latently infected B cells can be isolated by culturing B cells from individuals who have apparently cleared their EBV infection: in the absence of T cells, latently infected cells retaining the EBV genome become transformed into socalled immortal cell lines, the equivalent of tumorigenesis in vitro. Infected B cells occasionally undergo malignant transformation in vivo, giving rise to a Bcell lymphoma called Burkitt\u2019s lymphoma. In this lymphoma, expression of the peptide transporters TAP1 and TAP2 is downregulated (see Section 63), and so cells are unable to process endogenous antigens for presentation on HLA class I molecules (the human MHC class I). This deficiency provides one explanation for how these tumors escape attack by CD8 cytotoxic T cells. Patients with acquired and inherited immunodeficiencies of Tcell function have an increased risk of developing EBVassociated lymphomas, presumably as a result of a failure of immune surveillance."
        },
        {
            "id": "InternalMed_Harrison_8687",
            "title": "InternalMed_Harrison",
            "content": "The most common treatments for patients with typical B-cell CLL/small lymphocytic lymphoma have been chlorambucil or fludarabine, alone or in combination. Chlorambucil can be administered orally with few immediate side effects, while fludarabine is administered IV and is associated with significant immune suppression. However, fludarabine is by far the more active agent and is the only drug associated with a significant incidence of complete remission. The combination of rituximab (375\u2013500 mg/m2 day 1), fludarabine (25 mg/m2 days 2\u20134 on cycle 1 and days 1\u20133 in subsequent cycles), and cyclophosphamide (250 mg/m2 with fludarabine) achieves complete responses in 69% of patients, and those responses are associated with molecular remissions in half of the cases. Half the patients experience grade III or IV neutropenia. For young patients presenting with leukemia requiring therapy, regimens containing fludarabine are the treatment of choice. Because fludarabine is an effective second-line"
        },
        {
            "id": "Pharmacology_Katzung_4030",
            "title": "Pharmacology_Katzung",
            "content": "pseudo-lymphomas are reported rarely with TNF-\u03b1\u2013blocking agents, especially infliximab. TNF-\u03b1\u2013blocking agents may increase the risk of gastrointestinal ulcers and large bowel perforation including diverticular and appendiceal perforation."
        },
        {
            "id": "InternalMed_Harrison_8709",
            "title": "InternalMed_Harrison",
            "content": "Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma is the most common type of non-Hodgkin\u2019s lymphoma, representing approximately one-third of all cases. This lymphoma makes up the majority of cases in previous clinical trials of \u201caggressive\u201d or \u201cintermediate-grade\u201d lymphoma. Table 134-10 shows the clinical characteristics of diffuse large B-cell lymphoma."
        },
        {
            "id": "InternalMed_Harrison_8742",
            "title": "InternalMed_Harrison",
            "content": "The initial evaluation of a patient with a peripheral T-cell lymphoma should include the studies in Table 134-11 for staging patients with non-Hodgkin\u2019s lymphoma. Unfortunately, patients with peripheral T-cell lymphoma usually present with adverse prognostic factors, with >80% of patients having an IPI score \u22652 and >30% having an IPI score \u22654. As this would predict, peripheral T-cell lymphomas are associated with a poor outcome, and only 25% of the patients survive 5 years after diagnosis. Treatment regimens are the same as those used for diffuse large B-cell lymphoma (omitting rituximab), but patients with peripheral T-cell lymphoma have a poorer response to treatment. Because of this poor treatment outcome, hematopoietic stem cell transplantation is often considered early in the care of young patients."
        },
        {
            "id": "InternalMed_Harrison_8677",
            "title": "InternalMed_Harrison",
            "content": "MATURE (PERIPHERAL) B-CELL NEOPLASMS B-Cell Chronic Lymphoid Leukemia/Small Lymphocytic Lymphoma B-cell CLL/small lymphocytic lymphoma represents the most common lymphoid leukemia, and when presenting as a lymphoma, it accounts for ~7% of non-Hodgkin\u2019s lymphomas. Presentation can be as either leukemia or lymphoma. The major clinical characteristics of B-cell CLL/ small lymphocytic lymphoma are presented in Table 134-10. The diagnosis of typical B-cell CLL is made when an increased number of circulating lymphocytes (i.e., >4 \u00d7 109/L and usually Malignancies of Lymphoid Cells Abbreviation: MALT, mucosa-associated lymphoid tissue."
        },
        {
            "id": "Immunology_Janeway_4130",
            "title": "Immunology_Janeway",
            "content": "Herceptin is thought to act by blocking the binding of the natural ligand (so far unidentified) to this receptor, and by downregulating the level of expression of the receptor. The effects of this antibody can be enhanced when it is combined with conventional chemotherapy. Beyond blocking a growth signal for tumor cells, experiments in mice suggest that some of trastuzumab\u2019s antitumor effects also involve innate and adaptive immune responses, such as directing ADCC or inducing antitumor T-cell responses. A monoclonal antibody that has yielded excellent results in the treatment of non-Hodgkin\u2019s B-cell lymphoma is the anti-CD20 antibody rituximab, which triggers the apoptosis of B cells upon binding to CD20 on their surface (see Section 16-7). ADCC may be another mechanism by which rituximab acts, as its clinical efficacy has been linked to polymorphisms in activating Fc receptors."
        },
        {
            "id": "InternalMed_Harrison_8717",
            "title": "InternalMed_Harrison",
            "content": "not been validated as rigorously as the IPI and have not been uniformly applied clinically. Because a number of patients with diffuse large B-cell lymphoma are either initially refractory to therapy or relapse after apparently effective chemotherapy, 30\u201340% of patients will be candidates for salvage treatment at some point. Alternative combination chemotherapy regimens can induce complete remission in as many as 50% of these patients, but long-term disease-free survival is seen in \u226410%. Autologous bone marrow transplantation is superior to salvage chemotherapy at usual doses and leads to longterm disease-free survival in ~40% of patients whose lymphomas remain chemotherapy-sensitive after relapse."
        },
        {
            "id": "Pharmacology_Katzung_6979",
            "title": "Pharmacology_Katzung",
            "content": "Lymphoma appears to be increased in patients with untreated IBD. Anti-TNF agents may further increase the risk of lymphoma in this population, although the relative risk is uncertain. An increased number of cases of hepatosplenic T-cell lymphoma, a rare but usually fatal disease, have been noted in children and young adults, virtually all of whom have been on combined therapy with immunomodulators, anti-TNF agents, or corticosteroids. Anti-TNF agents may also be associated with an increased risk of nonmelanoma skin cancers."
        },
        {
            "id": "Surgery_Schwartz_2416",
            "title": "Surgery_Schwartz",
            "content": "is a purified gamma globulin obtained by immu-nizing horses with human thymocytes. These agents contain antibodies to T cells and B lymphocytes (B cells), integrins, and other adhesion molecules, thereby resulting in rapid depletion of peripheral lymphocytes. Typically, the total dose of Thymo-globulin is roughly 6 mg/kg, a dose that has been shown to con-fer adequate lymphocyte depletion and better allograft survival. Doses of 3 mg/kg may not effectively prevent acute rejection, but more doses and prolonged administration increase the risk of infection and the potential occurrence of lymphoma. Thymo-globulin administration causes a cytokine release syndrome, so premedications (acetaminophen and diphenhydramine) are usu-ally given. The principal side effects of Thymoglobulin include fever, chills, arthralgias, thrombocytopenia, leukopenia, and an increased incidence of a variety of infections.14,15Nondepleting AntibodiesBasiliximab (Simulect) is an anti-CD25 monoclonal antibody. The"
        },
        {
            "id": "InternalMed_Harrison_8688",
            "title": "InternalMed_Harrison",
            "content": "III or IV neutropenia. For young patients presenting with leukemia requiring therapy, regimens containing fludarabine are the treatment of choice. Because fludarabine is an effective second-line agent in patients with tumors unresponsive to chlorambucil, the latter agent is often chosen in elderly patients who require therapy. Bendamustine, an alkylating agent structurally related to nitrogen mustard, is highly effective and is vying with fludarabine as the primary treatment of choice. Patients who present with lymphoma (rather than leukemia) are also highly responsive to bendamustine, and some patients will receive a combination chemotherapy regimen used in other lymphomas such as CVP (cyclophosphamide, vincristine, and prednisone) or CHOP plus rituximab. Alemtuzumab (anti-CD52) is an antibody with activity in the disease, but it kills both B and T cells and is associated with more immune compromise than rituximab. Young patients with this disease can be candidates for bone marrow"
        },
        {
            "id": "Immunology_Janeway_4055",
            "title": "Immunology_Janeway",
            "content": "In addition to their use in preventing transplantation rejection, monoclonal antibodies can be used to treat certain autoimmune diseases, and the different immune mechanisms targeted are discussed in the next few sections. We start by discussing the use of depleting and nondepleting antibodies to remove lymphocytes nonspecifically. The anti-CD20 monoclonal antibody rituximab was originally developed to treat B-cell lymphomas, but has also been tried in treating certain autoimmune diseases. By ligating CD20, rituximab (Rituxan, MabThera) transduces a signal that induces lymphocyte apoptosis and depletes B cells for several months. Certain autoimmune diseases are believed to involve autoantibody-mediated pathogenesis. There is evidence for the efficacy of rituximab in some patients with autoimmune hemolytic anemia, SLE, rheumatoid arthritis, or type II mixed cryoglobulinemia, all of which have autoantibodies as a part of their clinical presentation. Although CD20 is not expressed on"
        },
        {
            "id": "Pathology_Robbins_2841",
            "title": "Pathology_Robbins",
            "content": "Immunophenotype. The tumor cells express surface IgM and IgD, the B cell antigen CD20, and CD5, and they contain high levels of cyclin D1 protein. Clinical Features. Most patients present with fatigue and lymphadenopathy and are found to have generalized disease involving the bone marrow, spleen, liver, and (often) the gastrointestinal tract. These tumors are moderately aggressive and incurable. The median survival is 4 to 6 years. Like CLL/SLL cells, mantle cell lymphoma cells depend on signals generated through BTK for survival, and it is hoped that newly available BTK inhibitors will improve clinical outcomes. This indolent B cell tumor arises most commonly in epithelial tissues such as the stomach, salivary glands, small and large bowel, lungs, orbit, and breast."
        },
        {
            "id": "InternalMed_Harrison_8676",
            "title": "InternalMed_Harrison",
            "content": "The treatment of patients with precursor B-cell ALL involves remission induction with combination chemotherapy, a consolidation phase that includes administration of high-dose systemic therapy and treatment to eliminate disease in the CNS, and a period of continuing therapy to prevent relapse and effect cure. The overall cure rate in children is 90%, whereas ~50% of adults are long-term disease-free survivors. This reflects the high proportion of adverse cytogenetic abnormalities seen in adults with precursor B-cell ALL. Precursor B-cell lymphoblastic lymphoma is a rare presentation of precursor B-cell lymphoblastic malignancy. These patients often have a rapid transformation to leukemia and should be treated as though they had presented with leukemia. The few patients who present with the disease confined to lymph nodes have a high cure rate."
        },
        {
            "id": "InternalMed_Harrison_8659",
            "title": "InternalMed_Harrison",
            "content": "provides the possibility to identify new genes with pathologic importance in lymphomas, the identification of patterns of gene expression with diagnostic and/or prognostic significance, and the identification of new therapeutic targets. Recognition of patterns of gene expression is complicated and requires sophisticated mathematical techniques. Early successes using this technology in lymphoma include the identification of previously unrecognized subtypes of diffuse large B-cell lymphoma whose gene expression patterns resemble either those of follicular center B cells or activated peripheral blood B cells. Patients whose lymphomas have a germinal center B-cell pattern of gene expression have a considerably better prognosis than those whose lymphomas have a pattern resembling activated peripheral blood B cells. This improved prognosis is independent of other known prognostic factors. Similar information is being generated in follicular lymphoma and mantle cell lymphoma. The challenge"
        },
        {
            "id": "Pathoma_Husain_152",
            "title": "Pathoma_Husain",
            "content": "3. Table 6.1: Differences Between Non-Hodgkin Lymphoma and Hodgkin Lymphoma Composition of mass Lymphoid cells Painless lymphadenopathy, usually arises Clinical with 'B' symptoms, usually arises in young Guides therapy; radiation is the mainstay of treatment. Fig. 6.16 Follicular lymphoma. A, Disruption of normal lymph node architecture by neoplastic follicles. B, Neoplastic follicles lacking tingible body macrophages. C, Reactive follicular hyperplasia with tingible body macrophages for comparison. II. FOLLICULAR LYMPHOMA A. Neoplastic proliferation of small B cells (CD20+) that form follicle-like nodules (Fig. 6.16A) B. Presents in late adulthood with painless lymphadenopathy C. Driven by t(l4;18) l. BCL2 on chromosome 18 translocates to the lg heavy chain locus on chromosome 14. 2. Results in overexpression of Bcl2, which inhibits apoptosis D. Treatment is reserved for patients who are symptomatic and involves low-dose chemotherapy or rituximab (anti-CD20 antibody)."
        },
        {
            "id": "Pharmacology_Katzung_6172",
            "title": "Pharmacology_Katzung",
            "content": "Rituximab is a chimeric murine-human monoclonal IgG1 (human Fc) that binds to the CD20 molecule on normal and malignant B lymphocytes and is approved for the therapy of patients with CD20-positive large-B-cell diffuse non-Hodgkin\u2019s lymphoma, and relapsed or refractory low-grade or follicular B-cell non-Hodgkin\u2019s lymphoma as a single agent or in combination with appropriate chemotherapy. It is approved for treatment of CLL in combination with chemotherapy. It is also approved for the treatment of rheumatoid arthritis in combination with methotrexate in patients for whom anti-TNF-\u03b1 therapy has failed. The most recent indication for rituximab is for the treatment of Wegener\u2019s granulomatosis and microscopic polyangiitis. The mechanism of action includes complement-mediated lysis, antibody-dependent cellular cytotoxicity, and induction of apoptosis in malignant lymphoma cells and in B cells involved in the pathogenesis of rheumatoid arthritis and granulomatosis and polyangiitis. In"
        },
        {
            "id": "InternalMed_Harrison_15008",
            "title": "InternalMed_Harrison",
            "content": "B Cells The predominant defect in B cells from HIV-infected individuals is one of aberrant cellular activation, which is reflected by increased propensity to terminal differentiation and immunoglobulin secretion and increased expression of markers of activation and exhaustion. As a result of activation and differentiation in vivo, B cells from HIV viremic patients manifest a decreased capacity to mount a proliferative response to ligation of the B cell antigen receptor and other B cell stimuli in vitro. B cells from HIV-infected individuals manifest enhanced spontaneous secretion of immunoglobulins in vitro, a process that reflects their highly differentiated state in vivo. There is also an increased incidence of EBV-related B cell lymphomas in HIV-infected individuals that are likely due to combined effects of defective T cell immune surveillance and increased turnover that increases the risk of oncogenesis. Untransformed B cells cannot be infected with HIV, although HIV or its"
        },
        {
            "id": "Pathology_Robbins_2838",
            "title": "Pathology_Robbins",
            "content": "Clinical Features. Follicular lymphoma mainly occurs in adults older than 50 years of age and affects males and females equally. It usually manifests as painless, generalized lymphadenopathy. The bone marrow is involved at diagnosis in approximately 80% of cases. Although the natural history is prolonged (overall median survival, approximately 10 years), follicular lymphoma is not curable, an unfortunate feature shared with most other relatively indolent lymphoid malignancies. As a result, therapy with cytotoxic drugs and rituximab (anti-CD20 antibody) is reserved for those with bulky, symptomatic disease. BTK and BCL2 inhibitors are also active in this disease and are being evaluated in clinical trials. In about 30% to 40% of patients, follicular lymphoma progresses to diffuse large B cell lymphoma. This transformation is an ominous event, as tumors arising from such conversions are much less curable than de novo diffuse large B cell lymphomas, described later."
        },
        {
            "id": "InternalMed_Harrison_8673",
            "title": "InternalMed_Harrison",
            "content": "CLINICAL FEATURES, TREATMENT, AND PROGNOSIS OF SPECIFIC LYMPHOID MALIGNANCIES PRECURSOR CELL B-CELL NEOPLASMS Precursor B-Cell Lymphoblastic Leukemia/Lymphoma The most common cancer in childhood is B-cell ALL. Although this disorder can also present as a lymphoma in either adults or children, presentation as lymphoma is rare. The malignant cells in patients with precursor B-cell lymphoblastic leukemia are most commonly of pre\u2013B cell origin. Patients typically 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Log rank test: p < .001 IPI: 4/5 (n = 171) 0.0 0 12345678910 FIGURE 134-4 Relationship of International Prognostic Index (IPI) to survival. Kaplan-Meier survival curves for 1300 patients with various kinds of lymphoma stratified according to the IPI. FIGURE 134-5 Acute lymphoblastic leukemia. The cells are hetero-geneous in size and have round or convoluted nuclei, high nuclear/ cytoplasmic ratio, and absence of cytoplasmic granules."
        }
    ],
    "scores": [
        0.025435447133927848,
        0.025197631351223493,
        0.024720530414000463,
        0.024010628649714684,
        0.02357234034689706,
        0.02181650935850264,
        0.020166912680040117,
        0.018329427519250083,
        0.017812105926860028,
        0.017637653351939064,
        0.017475875693336373,
        0.017028985507246377,
        0.01692624991110163,
        0.016823079596802223,
        0.01577384634417914,
        0.015542521994134896,
        0.015432098765432098,
        0.015316315205327414,
        0.0153011704253497,
        0.015281915480525212,
        0.015114196148678908,
        0.01501831501831502,
        0.014873653907666063,
        0.014796026210103572,
        0.014652211249463289,
        0.014647917332481091,
        0.014581396486764202,
        0.01448602948757604,
        0.01444906444906445,
        0.014407901435699012,
        0.014285714285714285,
        0.013911694946177704
    ]
}